Safety and efficacy of rasagiline in addition to levodopa for the treatment of idiopathic parkinson's disease: A meta-analysis of randomised controlled trials

European Neurology

Volumn 73, Issue 1-2, 2014, Pages 5-12

  Cai, Jiang Ping ^a   Chen, Wan Jin ^a   Lin, Yu ^a   Cai, Bin ^a   Wang, Ning ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Levodopa; Parkinson's disease; Rasagiline

Indexed keywords

ENTACAPONE; LEVODOPA; PLACEBO; RASAGILINE; ANTIPARKINSON AGENT; INDAN DERIVATIVE; NEUROPROTECTIVE AGENT;

ARTHRITIS; ARTICLE; BALANCE IMPAIRMENT; BRADYKINESIA; CARDIOTOXICITY; CEREBROVASCULAR ACCIDENT; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DYSKINESIA; FAINTNESS; HUMAN; MELANOMA; META ANALYSIS; MOTOR PERFORMANCE; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT DURATION; TREMOR; UNIFIED PARKINSON DISEASE RATING SCALE; URINARY TRACT INFECTION; VOMITING; COMBINATION DRUG THERAPY; FEMALE; MALE; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIPARKINSON AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INDANS; LEVODOPA; MALE; NEUROPROTECTIVE AGENTS; OUTCOME ASSESSMENT (HEALTH CARE); PARKINSON DISEASE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84927912978     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000367892     Document Type: Article

References (24)

1. Parkinson J. An essay on the shaking palsy. Goswell Street, London: Whittingham and Rowland, 1817
2. Twelves D, Perkins K, Counsell C. Systematic review of incidence studies of Parkinson's disease. Mov Disord 2003; 18: 19-31
3. WHO. Neurological disorders: public health challenges. Geneva: World Health Organisation; WHO Library Cataloguing-in-Publication Data, 2006
4. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1961; 276: 314-379
5. Nutt JG. Levodopa-induced dyskinesia: review, observations and speculations. Neurology 1990; 40: 340-345
6. Youdim MBH, Gross A, Finberg JPM. Rasagiline [N-propargyl-1R(+)-Aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 2001; 132: 500-506
7. Chen JJ, Swope DM, Dashtipour K. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Clin Ther 2007; 29: 1825-1849
8. Schapira A. Present and future drug treatment for Parkinson's disease. J Neurol Neurosurg Psychiatry 2005; 76: 1472-1478
9. Ahlskog JE, Uitti RJ. Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction? Neurology 2010; 74: 1143-1148
10. Olanow CW, Rascol O, Hauser R, et al. A double blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009; 361: 1268-1278
11. Cai J. Rasagiline for people receiving levodopa therapy in Parkinson's disease. PROSPERO 2013: CRD42013004186. Available from http://www.crd.york.ac.uk/PROSPERO/display-record.asp?ID=CRD42013004186
12. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Vol. Version 5.0.2. Available from www.cochranehandbook. org: The Cochrane Collaboration, 2011
13. Rascol O, Brooks DJ, Melamed E, et al; LARGO study group: Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, doubleblind, parallel-group trial. Lancet 2005; 365: 947-954
14. The Parkinson Study Group: A randomized placebo-controlled trial of rasagiline in levodopa-Treated patients with Parkinson's sisease and motor fluctuations-The PRESTO study. Arch Neurol 2005; 62: 241-248
15. Rabey JM, Sagi I, Huberman M, et al; Rasagiline Study Group: Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol 2000; 23: 324-330
16. Stocchi F, Rabey JM. Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease. Eur J Neurol 2011; 18: 1373-1378
17. Fahn S, Elton RL; UPDRS development committee: Unified Parkinson's Disease Rating Scale; in Fahn S, Marsden CD, Calne D, Goldstein M (eds): Recent developments in Parkinson's disease. Florham Park, NJ, USA: Macmillan, 1987, pp 153-164
18. Welsh M, McDermott MP, Holloway RG, et al; Parkinson Study Group: Development and testing of the Parkinson's disease quality of life scale. Mov Disord 2003; 18: 637-645
19. Schott G, Pachl H, Limbach U. The financing of drug trials by pharmaceutical companies and its consequences. Dtsch Arztebl Int 2010; 107: 279-285
20. Wooten GF, Currie LJ, Bovbjerg VE, et al. Are men at greater risk of Parkinson's disease than women? J Neurol Neurosurg Psychiatry 2004; 75: 637-639
21. Taylor KSM, Cook JA, Counsell CE. Heterogeneity in male to female risk for Parkinson's disease. J Neurol Neurosurg Psychiatry 2007; 78: 905-912
22. Clarke CE. Rasagiline for motor complications in Parkinson's disease. Lancet 2005; 365: 914-915
23. Rasagiline in levodopa-Treated Parkinson's patients with motor fluctuations in China (CHORAL). ClinicalTrials.gov Identifier NCT01479530, trial sponsors: H Lundbeck A/S. http://clinicaltrials.gov/ct2/show/NCT 01479530 (accessed March 28, 2013
24. A large randomised assessment of the relative cost-effectiveness of classes of drugs for Parkinson's disease (PD MED). http://www. pdmed.bham.ac.uk (accessed March 28, 2013